lvrachЛечащий ВрачLechaschi Vrach1560-51752687-1181lvrach-562Research ArticleСтатьиКишечный микробиом как терапевтическая мишень в лечении хронической неалкогольной болезни печениIntestinal microbiom as a therapeutic target in treatment of chronic non-alcoholic fat liver diseaseПлотниковаЕ. Ю.PlotnikovaE. Yu.eka-pl@rambler.ruЗахароваЮ. В.ZakharovaYu. V.noemail@neicon.ruГрачеваТ. Ю.GrachevaT. Yu.noemail@neicon.ruФГБОУ ВО КемГМУ МЗ РФРоссия201823062021083838Copyright © Плотникова Е.Ю., Захарова Ю.В., Грачева Т.Ю., 20212021Плотникова Е.Ю., Захарова Ю.В., Грачева Т.Ю.Plotnikova E.Y., Zakharova Y.V., Gracheva T.Y.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.lvrach.ru/jour/article/view/562

Поскольку стандартные диетические изменения и изменения образа жизни и патогенно-ориентированные методы лечения неалкогольной жировой болезни печени часто неэффективны, необходимы новые подходы, направленные на другие мишени. В условиях, связанных с поврежденным кишечным барьером («протекающая кишка»), оси «кишка–печень» можно улучшить естественные взаимодействия между кишечными бактериями и пептическими рецепторами, тем самым способствуя следующему каскаду событий: окислительный стресс, резистентность к инсулину, воспаление печени и фиброз. В статье также обсуждается возможность модуляции микробиоты кишечника пробиотиками.

While standard diets, changes in the way of life, and pathogenically oriented methods of treatment of non-alcoholic fat liver disease are often ineffective, it is necessary to develop new approaches aimed to other targets. Under the conditions of damaged intestinal barrier (“leaking bowel”), and bowel- liver axis, it is possible to improve natural interaction between the intestinal bacteria and peptic receptors, which contributes to the following course of events: oxidative stress, insulin-resistance, liver inflammation and fibrosis. The article also highlights possibility of intestinal microbiota modulation with probiotics. 

КоллоквиумГепатологияПробиотикиКишечная микробиотаСиндром избыточного бактериального ростаНеалкогольная жировая болезнь печениprobioticsintestinal microbiotasyndrome of excessive bacterial growthnon-alcoholic fat liver diseaseReferencesСайт «Жемчужина мысли». https://www.inpearls.ru/author/26504.Сайт «Жемчужина мысли». https://www.inpearls.ru/author/26504.Bj?rnsson E. The clinical aspects of non-alcoholic fatty liver disease // Minerva Gastroenterol Dietol. 2008; 54: 7–18.Bj?rnsson E. The clinical aspects of non-alcoholic fatty liver disease // Minerva Gastroenterol Dietol. 2008; 54: 7–18.Angulo P. Nonalcoholic fatty liver disease // N Engl J Med. 2002; 346: 1221–1231.Angulo P. Nonalcoholic fatty liver disease // N Engl J Med. 2002; 346: 1221–1231.Brunt E. M., Janney C. G., Di Bisceglie A. M., Neuschwander-Tetri B. A., Bacon B. R. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions // Am J Gastroenterol. 1999; 94: 2467–2674.Brunt E. M., Janney C. G., Di Bisceglie A. M., Neuschwander-Tetri B. A., Bacon B. R. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions // Am J Gastroenterol. 1999; 94: 2467–2674.Chalasani N., Younossi Z., Lavine J. E., Diehl A. M., Brunt E. M., Cusi K., Charlton M. et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology // Gastroenterology. 2012; 142: 1592–1609.Chalasani N., Younossi Z., Lavine J. E., Diehl A. M., Brunt E. M., Cusi K., Charlton M. et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology // Gastroenterology. 2012; 142: 1592–1609.Day C. Pathogenesis of steatohepatitis // Best Pract Res Clin Gastroenterol. 2002; 16: 663–678.Day C. Pathogenesis of steatohepatitis // Best Pract Res Clin Gastroenterol. 2002; 16: 663–678.Farrell G. C., Larter C. Z. Nonalcoholic fatty liver disease: from steatosis to cirrhosis // Hepatology. 2006; 43: S99–S112.Farrell G. C., Larter C. Z. Nonalcoholic fatty liver disease: from steatosis to cirrhosis // Hepatology. 2006; 43: S99–S112.McCullough A. J. Pathophysiology of nonalcoholic steatohepatitis // J Clin Gastroenterol. 2006; 40 Suppl 1: S17–29.McCullough A. J. Pathophysiology of nonalcoholic steatohepatitis // J Clin Gastroenterol. 2006; 40 Suppl 1: S17–29.Duvnjak M., Leroti? I., Barsi? N., Tomasi? V., Virovi? Juki? L., Velagi? V. Pathogenesis and management issues for non-alcoholic fatty liver disease // World J Gastroenterol. 2007; 13: 4539–4550.Duvnjak M., Leroti? I., Barsi? N., Tomasi? V., Virovi? Juki? L., Velagi? V. Pathogenesis and management issues for non-alcoholic fatty liver disease // World J Gastroenterol. 2007; 13: 4539–4550.Kojima H., Sakurai S., Uemura M., Fukui H., Morimoto H., Tamagawa Y. Mitochondrial abnormality and oxidative stress in nonalcoholic steatohepatitis // Alcohol Clin Exp Res. 2007; 31: S61–66.Kojima H., Sakurai S., Uemura M., Fukui H., Morimoto H., Tamagawa Y. Mitochondrial abnormality and oxidative stress in nonalcoholic steatohepatitis // Alcohol Clin Exp Res. 2007; 31: S61–66.Solga S. F., Diehl A. Non-alcoholic fatty liver disease: lumen–liver interactions and possible role for probiotics // J Hepatol. 2003; 38: 681–687.Solga S. F., Diehl A. Non-alcoholic fatty liver disease: lumen–liver interactions and possible role for probiotics // J Hepatol. 2003; 38: 681–687.Dowman J. K., Tomlinson J. W., Newsome P. N. Pathogenesis of non-alcoholic fatty liver disease // QJM. 2010; 103: 71–83.Dowman J. K., Tomlinson J. W., Newsome P. N. Pathogenesis of non-alcoholic fatty liver disease // QJM. 2010; 103: 71–83.Киясов А. П., Гумерова А. А., Титова М. А. Овальные клетки — предполагаемые стволовые клетки печени или гепатобласты? // Гены & Клетки. 2006. Т. I, № 2, с. 55–58.Киясов А. П., Гумерова А. А., Титова М. А. Овальные клетки — предполагаемые стволовые клетки печени или гепатобласты? // Гены & Клетки. 2006. Т. I, № 2, с. 55–58.Farrell G. Is bacterial ash the flash that ignites NASH? // Gut. 2001; 48: 148–149.Farrell G. Is bacterial ash the flash that ignites NASH? // Gut. 2001; 48: 148–149.Loguercio C., de Simone T., Federico A., Terracciano F., Tuccillo C., Di Chicco M. et al. Gut-liver axis: a new point of attack to treat chronic liver damage? // Am J Gastroenterol. 2002; 97: 2144–2146.Loguercio C., de Simone T., Federico A., Terracciano F., Tuccillo C., Di Chicco M. et al. Gut-liver axis: a new point of attack to treat chronic liver damage? // Am J Gastroenterol. 2002; 97: 2144–2146.Solga S. F., Diehl A. Non-alcoholic fatty liver disease: lumen-liver interactions and possible role for probiotics // J Hepatol. 2003; 38: 681–687.Solga S. F., Diehl A. Non-alcoholic fatty liver disease: lumen-liver interactions and possible role for probiotics // J Hepatol. 2003; 38: 681–687.Iacono A., Raso G. M., Canani R. B., Calignano A., Meli R. Probiotics as an emerging therapeutic strategy to treat NAFLD: focus on molecular and biochemical mechanisms // J Nutr Biochem. 2011; 22: 699–711.Iacono A., Raso G. M., Canani R. B., Calignano A., Meli R. Probiotics as an emerging therapeutic strategy to treat NAFLD: focus on molecular and biochemical mechanisms // J Nutr Biochem. 2011; 22: 699–711.Eslamparast T., Eghtesad S., Hekmatdoost A., Poustchi H. Probiotics and nonalcoholic fatty liver disease // Middle East J Dig Dis. 2013, Jul; 5 (3): 129–136.Eslamparast T., Eghtesad S., Hekmatdoost A., Poustchi H. Probiotics and nonalcoholic fatty liver disease // Middle East J Dig Dis. 2013, Jul; 5 (3): 129–136.Zeuzem S. Gut-liver axis // Int J Colorectal Dis. 2000; 15: 59–82.Zeuzem S. Gut-liver axis // Int J Colorectal Dis. 2000; 15: 59–82.Laflamme N., Rivest S. Toll-like receptor 4: the missing link of the cerebral innate immune response triggered by circulating gram-negative bacterial cell wall components // FASEB J. 2001; 15: 155–163.Laflamme N., Rivest S. Toll-like receptor 4: the missing link of the cerebral innate immune response triggered by circulating gram-negative bacterial cell wall components // FASEB J. 2001; 15: 155–163.Berg R. D., Garlington A. W. Translocation of certain indigenous bacteria from the gastrointestinal tract to the mesenteric lymph nodes and other organs in a gnotobiotic mouse model // Infect Immun. 1979; 23: 403–411.Berg R. D., Garlington A. W. Translocation of certain indigenous bacteria from the gastrointestinal tract to the mesenteric lymph nodes and other organs in a gnotobiotic mouse model // Infect Immun. 1979; 23: 403–411.Jacob A., Goldberg P., Bloom N., Degenshein G., Kozinn P. Endotoxin and bacteria in portal blood // Gastroenterology. 1977; 72: 1268.Jacob A., Goldberg P., Bloom N., Degenshein G., Kozinn P. Endotoxin and bacteria in portal blood // Gastroenterology. 1977; 72: 1268.Nolan J. P. Endotoxin, reticuloendothelial function, and liver injury // Hepatology. 1981; 1: 458–465.Nolan J. P. Endotoxin, reticuloendothelial function, and liver injury // Hepatology. 1981; 1: 458–465.Mathison J. C., Ulevitch R. J. The clearance, tissue distribution, and cellular localization of intravenously injected lipopolysaccharide in rabbits // J Immunol. 1979; 123: 2133–2143.Mathison J. C., Ulevitch R. J. The clearance, tissue distribution, and cellular localization of intravenously injected lipopolysaccharide in rabbits // J Immunol. 1979; 123: 2133–2143.Ruiter D., van der Meulen J., Brouwer A., Hummel M., Mauw B., van der Ploeg J. et al. Uptake by liver cells of endotoxin following its intravenous injection // Lab Invest. 1981; 45: 38–45.Ruiter D., van der Meulen J., Brouwer A., Hummel M., Mauw B., van der Ploeg J. et al. Uptake by liver cells of endotoxin following its intravenous injection // Lab Invest. 1981; 45: 38–45.Jirillo E., Caccavo D., Magrone T., Piccigallo E., Amati L., Lembo A. et al. Review: The role of the liver in the response to LPS: experimental and clinical findings // J Endotoxin Res. 2002; 8: 319–327.Jirillo E., Caccavo D., Magrone T., Piccigallo E., Amati L., Lembo A. et al. Review: The role of the liver in the response to LPS: experimental and clinical findings // J Endotoxin Res. 2002; 8: 319–327.Compare D., Coccoli P., Rocco A., Nardone O., de Maria S., Carten? M. et al. Gut-liver axis: The impact of gut microbiota on non alcoholic fatty liver disease // Nutr Metab Cardiovasc Dis. 2012; 22: 471–476.Compare D., Coccoli P., Rocco A., Nardone O., de Maria S., Carten? M. et al. Gut-liver axis: The impact of gut microbiota on non alcoholic fatty liver disease // Nutr Metab Cardiovasc Dis. 2012; 22: 471–476.Schrezenmeir J., de Vrese M. Probiotics, prebiotics, and synbiotics-approaching a definition // Am J Clin Nutr. 2001; 73: 361 S–4 S.Schrezenmeir J., de Vrese M. Probiotics, prebiotics, and synbiotics-approaching a definition // Am J Clin Nutr. 2001; 73: 361 S–4 S.He M., Shi B. Gut microbiota as a potential target of metabolic syndrome: The role of probiotics and prebiotics. 2017; 7 (1, article no. 54). DOI: 10.1186/s13578–017–0183–1.He M., Shi B. Gut microbiota as a potential target of metabolic syndrome: The role of probiotics and prebiotics. 2017; 7 (1, article no. 54). DOI: 10.1186/s13578–017–0183–1.Vanderhoof J. A., Whitney D. B., Antonson D. L., Hanner T. L., Lupo J. V., Young R. J. Lactobacillus GG in the prevention of antibiotic-associated diarrhea in children // J Pediatr. 1999; 135: 564–568.Vanderhoof J. A., Whitney D. B., Antonson D. L., Hanner T. L., Lupo J. V., Young R. J. Lactobacillus GG in the prevention of antibiotic-associated diarrhea in children // J Pediatr. 1999; 135: 564–568.Food and Agricultural Organization of the United Nations and World Health Organization. Joint FAO/WHO working group report on drafting guidelines for the evaluation of probiotics in food. 2002. URL: http://www.un.org/youthenvoy/2013/09/fao-food-and-agriculture-organization-of-the-united-nations/.Food and Agricultural Organization of the United Nations and World Health Organization. Joint FAO/WHO working group report on drafting guidelines for the evaluation of probiotics in food. 2002. URL: http://www.un.org/youthenvoy/2013/09/fao-food-and-agriculture-organization-of-the-united-nations/.Cesaro C., Tiso A., Del Prete A., Cariello R., Tuccillo C., Cotticelli G. et al. Gut microbiota and probiotics in chronic liver diseases // Dig Liver Dis. 2011; 43: 431–438.Cesaro C., Tiso A., Del Prete A., Cariello R., Tuccillo C., Cotticelli G. et al. Gut microbiota and probiotics in chronic liver diseases // Dig Liver Dis. 2011; 43: 431–438.Frazier T. H., DiBaise J. K., McClain C. J. Gut Microbiota, Intestinal Permeability, Obesity-Induced Inflammation, and Liver Injury // JPEN J Parenter Enteral Nutr. 2011; 35: 14 S–20S.Frazier T. H., DiBaise J. K., McClain C. J. Gut Microbiota, Intestinal Permeability, Obesity-Induced Inflammation, and Liver Injury // JPEN J Parenter Enteral Nutr. 2011; 35: 14 S–20S.Lavekar S., Raje D. V., Manohar T., Lavekar A. A. Role of Probiotics in the Treatment of Nonalcoholic Fatty Liver Disease: A Meta-analysis Anurag // Euroasian J Hepatogastroenterol. 2017, Jul-Dec; 7 (2): 130–137.Lavekar S., Raje D. V., Manohar T., Lavekar A. A. Role of Probiotics in the Treatment of Nonalcoholic Fatty Liver Disease: A Meta-analysis Anurag // Euroasian J Hepatogastroenterol. 2017, Jul-Dec; 7 (2): 130–137.Alisi A., Bedogni G., Baviera G., Giorgio V., Porro E., Paris C., Giammaria P., Reali L., Anania F., Nobili V. Randomised clinical trial: the beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis // Aliment Pharmacol Ther. 2014, Jun; 39 (11): 1276–1285.Alisi A., Bedogni G., Baviera G., Giorgio V., Porro E., Paris C., Giammaria P., Reali L., Anania F., Nobili V. Randomised clinical trial: the beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis // Aliment Pharmacol Ther. 2014, Jun; 39 (11): 1276–1285.Shavakhi A., Minakari M., Firouzian H., Assali R., Hekmatdoost A., Ferns G. Effect of a Probiotic and Metformin on Liver Aminotransferases in Non-alcoholic Steatohepatitis: A Double Blind Randomized Clinical Trial // Int J Prev Med. 2013; 4: 531–537.Shavakhi A., Minakari M., Firouzian H., Assali R., Hekmatdoost A., Ferns G. Effect of a Probiotic and Metformin on Liver Aminotransferases in Non-alcoholic Steatohepatitis: A Double Blind Randomized Clinical Trial // Int J Prev Med. 2013; 4: 531–537.Loguercio C., Federico A., Tuccillo C., Terracciano F., D’Auria M. V., De Simone C., del Vecchio Blanco C. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases // J Clin Gastroenterol. 2005; 39: 540–543.Loguercio C., Federico A., Tuccillo C., Terracciano F., D’Auria M. V., De Simone C., del Vecchio Blanco C. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases // J Clin Gastroenterol. 2005; 39: 540–543.Vajro P., Mandato C., Licenziati M. R., Franzese A., Vitale D. F., Lenta S., Caropreso M., Vallone G., Meli R. Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease // J. Pediatr. Gastroenterol. Nutr. 2011; 52: 740–743.Vajro P., Mandato C., Licenziati M. R., Franzese A., Vitale D. F., Lenta S., Caropreso M., Vallone G., Meli R. Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease // J. Pediatr. Gastroenterol. Nutr. 2011; 52: 740–743.Aller R., De Luis D. A., Izaola O., Conde R., Gonzalez Sagrado M., Primo D., de La Fuente B., Gonzalez J. Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: A double blind randomized clinical trial // Eur. Rev. Med. Pharmacol. Sci. 2011; 15: 1090–1095.Aller R., De Luis D. A., Izaola O., Conde R., Gonzalez Sagrado M., Primo D., de La Fuente B., Gonzalez J. Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: A double blind randomized clinical trial // Eur. Rev. Med. Pharmacol. Sci. 2011; 15: 1090–1095.Malaguarnera M., Vacante M., Antic T., Giordano M., Chisari G., Acquaviva R., Mastrojeni S., Malaguarnera G., Mistretta A., Li Volti G. et al. Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis // Dig Dis Sci. 2012; 57: 545–553.Malaguarnera M., Vacante M., Antic T., Giordano M., Chisari G., Acquaviva R., Mastrojeni S., Malaguarnera G., Mistretta A., Li Volti G. et al. Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis // Dig Dis Sci. 2012; 57: 545–553.Wong V. W., Won G. L., Chim A. M., Chu W. C., Yeung D. K., Li K. C., Chan H. L. Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study // Ann Hepatol. 2013; 12: 256–262.Wong V. W., Won G. L., Chim A. M., Chu W. C., Yeung D. K., Li K. C., Chan H. L. Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study // Ann Hepatol. 2013; 12: 256–262.Eslamparast T., Poustchi H., Zamani F., Sharafkhah M., Malekzadeh R., Hekmatdoost A. Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study // Am J Clin Nutr. 2014; 99: 535–542.Eslamparast T., Poustchi H., Zamani F., Sharafkhah M., Malekzadeh R., Hekmatdoost A. Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study // Am J Clin Nutr. 2014; 99: 535–542.Hakansson A., Molin G. Gut microbiota and inflammation // Nutrients. 2011; 3: 637–682.Hakansson A., Molin G. Gut microbiota and inflammation // Nutrients. 2011; 3: 637–682.Racanelli V., Rehermann B. The liver as an immunological organ. Hepatology. 2006; 43: S54–S62.Racanelli V., Rehermann B. The liver as an immunological organ. Hepatology. 2006; 43: S54–S62.Su G. L. Lipopolysaccharides in liver injury: molecular mechanisms of Kupffer cell activation // Am J Physiol Gastrointest Liver Physiol. 2002; 283: G256–265.Su G. L. Lipopolysaccharides in liver injury: molecular mechanisms of Kupffer cell activation // Am J Physiol Gastrointest Liver Physiol. 2002; 283: G256–265.Tobias P. S., Soldau K., Gegner J. A., Mintz D., Ulevitch R. J. Lipopolysaccharide binding protein-mediated complexation of lipopolysaccharide with soluble CD14 // J Biol Chem. 1995; 270: 10482–10488.Tobias P. S., Soldau K., Gegner J. A., Mintz D., Ulevitch R. J. Lipopolysaccharide binding protein-mediated complexation of lipopolysaccharide with soluble CD14 // J Biol Chem. 1995; 270: 10482–10488.Baldwin Jr. A. S. The NF-?B and I?B proteins: new discoveries and insights // Annu Rev Immunol. 1996; 14: 649–683.Baldwin Jr. A. S. The NF-?B and I?B proteins: new discoveries and insights // Annu Rev Immunol. 1996; 14: 649–683.Madsen K., Cornish A., Soper P., McKaigney C., Jijon H., Yachimec C. et al. Probiotic bacteria enhance murine and human intestinal epithelial barrier function // Gastroenterology. 2001; 121: 580–591.Madsen K., Cornish A., Soper P., McKaigney C., Jijon H., Yachimec C. et al. Probiotic bacteria enhance murine and human intestinal epithelial barrier function // Gastroenterology. 2001; 121: 580–591.Resta-Lenert S., Barrett K. Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive Escherichia coli (EIEC) // Gut. 2003; 52: 988–997.Resta-Lenert S., Barrett K. Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive Escherichia coli (EIEC) // Gut. 2003; 52: 988–997.Ghosh S., van Heel D., Playford R. Probiotics in inflammatory bowel disease: is it all gut flora modulation? // Gut. 2004; 53: 620–622.Ghosh S., van Heel D., Playford R. Probiotics in inflammatory bowel disease: is it all gut flora modulation? // Gut. 2004; 53: 620–622.Li Z., Yang S., Lin H., Huang J., Watkins P. A., Moser A. B. et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease // Hepatology. 2003; 37: 343–350.Li Z., Yang S., Lin H., Huang J., Watkins P. A., Moser A. B. et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease // Hepatology. 2003; 37: 343–350.Haller D., Bode C., Hammes W., Pfeifer A., Schiffrin E., Blum S. Non-pathogenic bacteria elicit a differential cytokine response by intestinal epithelial cell/leucocyte co-cultures // Gut. 2000; 47: 79–87.Haller D., Bode C., Hammes W., Pfeifer A., Schiffrin E., Blum S. Non-pathogenic bacteria elicit a differential cytokine response by intestinal epithelial cell/leucocyte co-cultures // Gut. 2000; 47: 79–87.Gr?nlund M., Arvilommi H., Kero P., Lehtonen O., Isolauri E. Importance of intestinal colonisation in the maturation of humoral immunity in early infancy: a prospective follow up study of healthy infants aged 0–6 months // Arch Dis Child Fetal Neonatal Ed. 2000; 83: F186–192.Gr?nlund M., Arvilommi H., Kero P., Lehtonen O., Isolauri E. Importance of intestinal colonisation in the maturation of humoral immunity in early infancy: a prospective follow up study of healthy infants aged 0–6 months // Arch Dis Child Fetal Neonatal Ed. 2000; 83: F186–192.Pagano G., Pacini G., Musso G., Gambino R., Mecca F., Depetris N. et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association // Hepatology. 2002; 35: 367–372.Pagano G., Pacini G., Musso G., Gambino R., Mecca F., Depetris N. et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association // Hepatology. 2002; 35: 367–372.Farrell G. C. Signalling links in the liver: knitting SOCS with fat and inflammation // J Hepatol. 2005; 43: 193–196.Farrell G. C. Signalling links in the liver: knitting SOCS with fat and inflammation // J Hepatol. 2005; 43: 193–196.Brun P., Castagliuolo I., Di Leo V., Buda A., Pinzani M., Pal? G. et al. Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis // Am J Physiol Gastrointest Liver Physiol. 2007; 292: G518–525.Brun P., Castagliuolo I., Di Leo V., Buda A., Pinzani M., Pal? G. et al. Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis // Am J Physiol Gastrointest Liver Physiol. 2007; 292: G518–525.Cani P. D., Amar J., Iglesias M. A., Poggi M., Knauf C., Bastelica D. et al. Metabolic endotoxemia initiates obesity and insulin resistance // Diabetes. 2007; 56: 1761–1772.Cani P. D., Amar J., Iglesias M. A., Poggi M., Knauf C., Bastelica D. et al. Metabolic endotoxemia initiates obesity and insulin resistance // Diabetes. 2007; 56: 1761–1772.Creely S. J., McTernan P. G., Kusminski C. M., Da Silva N., Khanolkar M., Evans M. et al. Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes // Am J Physiol Endocrinol Metab. 2007; 292: E740–647.Creely S. J., McTernan P. G., Kusminski C. M., Da Silva N., Khanolkar M., Evans M. et al. Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes // Am J Physiol Endocrinol Metab. 2007; 292: E740–647.Peraldi P., Spiegelman B. TNF-? and insulin resistance: summary and future prospects // Mol Cell Biochem. 1998; 182: 169–175.Peraldi P., Spiegelman B. TNF-? and insulin resistance: summary and future prospects // Mol Cell Biochem. 1998; 182: 169–175.Al-Salami H., Butt G., Fawcett J. P., Tucker I. G., Golocorbin-Kon S., Mikov M. Probiotic treatment reduces blood glucose levels and increases systemic absorption of gliclazide in diabetic rats // Eur J Drug Metab Pharmacokinet. 2008; 33: 101–106.Al-Salami H., Butt G., Fawcett J. P., Tucker I. G., Golocorbin-Kon S., Mikov M. Probiotic treatment reduces blood glucose levels and increases systemic absorption of gliclazide in diabetic rats // Eur J Drug Metab Pharmacokinet. 2008; 33: 101–106.Bataller R., Brenner D. A. Liver fibrosis // J Clin Invest. 2005; 115: 209–218.Bataller R., Brenner D. A. Liver fibrosis // J Clin Invest. 2005; 115: 209–218.Seki E., de Minicis S., ?sterreicher C. H., Kluwe J., Osawa Y., Brenner D. A. et al. TLR4 enhances TGF-? signaling and hepatic fibrosis // Nat Med. 2007; 13: 1324–1332.Seki E., de Minicis S., ?sterreicher C. H., Kluwe J., Osawa Y., Brenner D. A. et al. TLR4 enhances TGF-? signaling and hepatic fibrosis // Nat Med. 2007; 13: 1324–1332.Brun P., Castagliuolo I., Pinzani M., Pal? G., Martines D. Exposure to bacterial cell wall products triggers an inflammatory phenotype in hepatic stellate cells // Am J Physiol Gastrointest Liver Physiol. 2005; 289: G571–578.Brun P., Castagliuolo I., Pinzani M., Pal? G., Martines D. Exposure to bacterial cell wall products triggers an inflammatory phenotype in hepatic stellate cells // Am J Physiol Gastrointest Liver Physiol. 2005; 289: G571–578.Paik Y. H., Schwabe R. F., Bataller R., Russo M. P., Jobin C., Brenner D. A. Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells // Hepatology. 2003; 37: 1043–1055.Paik Y. H., Schwabe R. F., Bataller R., Russo M. P., Jobin C., Brenner D. A. Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells // Hepatology. 2003; 37: 1043–1055.Bataller R., Brenner D. A. Liver fibrosis // J Clin Invest. 2005; 115: 209–218.Bataller R., Brenner D. A. Liver fibrosis // J Clin Invest. 2005; 115: 209–218.Плотникова Е. Ю., Захарова Ю. В. Место пробиотиков в современной клинической практике // Consilium Medicum. Педиатрия. 2018; 1: 30–34.Плотникова Е. Ю., Захарова Ю. В. Место пробиотиков в современной клинической практике // Consilium Medicum. Педиатрия. 2018; 1: 30–34.

The authors declare that there are no conflicts of interest present.